Seth Porter

1.0k citations

21 papers · 799 indexed · h-index 11

Impact in

Pulmonary and Respiratory Medicine top 10%
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension Research and Treatments
Biochemistry top 10%

Papers in ⓘ

Pulmonary and Respiratory Medicine 12
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 8
- Renal cell carcinoma treatment 4
- Pulmonary Hypertension Research and Treatments 2
Biochemistry 2
- Blood transfusion and management 2

Co-authors: Jonathan Goldin (8 shared papers)Ganesh Raghu (5 shared papers)Kevin R. Flaherty (4 shared papers)Thomas B. Neff (7 shared papers)Mary Beth Scholand (4 shared papers)Stanley C. Froehner (1 shared paper)Elias Kouchakji (8 shared papers)Ming Zhong (6 shared papers)
Journals: Journal of Clinical Oncology (5 papers)Transfusion (2 papers)Journal of Pharmaceutical Sciences (1 paper)ESMO Open (1 paper)The Lancet Respiratory Medicine (1 paper)
Partner nations: United States Italy Germany

In The Last Decade

Seth Porter

21 papers receiving 771 citations

Peers

Countries citing papers authored by Seth Porter

Since Specialization

Citations

This map shows the geographic impact of Seth Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth Porter more than expected).

Fields of papers citing papers by Seth Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth Porter. The network helps show where Seth Porter may publish in the future.

Co-authors

The 25 scholars most cited alongside Seth Porter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Seth Porter Line = papers co-authored together Seth Porter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial The Lancet Respiratory Medicine ·Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel, Carlo Albera, David J. Lederer, Kevin R. Flaherty, Neil Ettinger, Rafael L. Perez, Mary Beth Scholand, Jonathan Goldin, Kin-Hung P. Yu, Thomas B. Neff, Seth Porter, Ming Zhong, Eduard Gorina, Elias Kouchakji, Ganesh Raghu	2019	215
2	FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis European Respiratory Journal ·Ganesh Raghu, Mary Beth Scholand, João A. de Andrade, Lisa Lancaster, Yolanda Mageto, Jonathan Goldin, Kevin K. Brown, Kevin R. Flaherty, Mark L. Wencel, Jack Wanger, Thomas B. Neff, Frank H. Valone, John L. Stauffer, Seth Porter	2016	140
3	Human Immune Response to Recombinant Human Proteins Journal of Pharmaceutical Sciences ·Seth Porter	2001	129
4	Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylase British Journal of Pharmacology ·William C. Stanley, Bin Li, Douglas W. Bonhaus, Lowell G. Johnson, Keiho Lee, Seth Porter, Keith A. M. Walker, G. Martínez, Richard M. Eglen, R.L. Whiting, Sharath S. Hegde	1997	78
5	Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer ESMO Open ·Vincent J. Picozzi, Adnan Alseidi, Jordan Winter, Michael J. Pishvaian, Kabir Mody, John A. Glaspy, Timothy Larson, Marc Matrana, Mairead Carney, Seth Porter, Elias Kouchakji, Flavio G. Rocha, Ewa Carrier	2020	54
6	Interaction of the 43K protein with components of Torpedo postsynaptic membranes Biochemistry ·Seth Porter, Stanley C. Froehner	1985	44
7	Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment Transfusion ·Lily Lin, Maureen G. Conlan, John W. Tessman, George D. Cimino, Seth Porter	2005	40
8	Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial Transfusion ·Alvaro A. Pineda, Jeffrey McCullough, Richard J. Benjamin, Ritchard G. Cable, Ronald G. Strauss, Edwin A. Burgstaler, Seth Porter, Lily Lin, Peyton Metzel, Maureen G. Conlan, (unknown)	2006	22
9	PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients Eduard Gorina, Luca Richeldi, Ganesh Raghu, E. Fernandez Perez, Ulrich Costabel, Carlo Albera, David J. Lederer, Kevin R. Flaherty, Neil Ettinger, Peter A. Bercz, Bhanu Singh, Rafael L. Perez, Jonathan Goldin, Elias Kouchakji, Seth Porter	2017	18
10	Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients. Journal of Clinical Oncology ·Vincent J. Picozzi, Michael J. Pishvaian, Kabir Mody, Jordan M. Winter, John A. Glaspy, Tim Larson, Marc Matrana, Khalil G. Saikali, Mairead Carney, Seth Porter, Peony Yu, Elias Kouchakji, Ewa Carrier	2018	15
11	FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology ·Vincent J. Picozzi, J. Marc Pipas, Albert C. Koong, Amato J. Giaccia, Nathan Bahary, Smitha Krishnamurthi, Charles D. Lopez, Peter J. O’Dwyer, Katharina Modelska, Mairead Carney, Heather Hernandez, James Chou, Tyson Lee, Ming Zhong, Seth Porter, Tom Neff, Frank H. Valone	2014	10
12	FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma Vincent J. Picozzi, J. Marc Pipas, Albert C. Koong, Amato J. Giaccia, Nathan Bahary, Smitha Krishnamurthi, Charles D. Lopez, Peter J. O’Dwyer, Katharina Modelska, Mairead Carney, James Chou, Ming Zhong, Stefan Hemmerich, Dongxia Li, Ewa Carrier, Seth Porter, Thomas B. Neff, Frank H. Valone	2016	8
13	Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). Journal of Clinical Oncology ·Vincent J. Picozzi, Flavio G. Rocha, Scott Helton, Michael J. Pishvaian, Patrick G. Jackson, Kabir Mody, Horacio J. Asbun, Mairead Carney, Tina Etheridge, Thomas B. Neff, Seth Porter, Ming Zhong, Frank H. Valone, Elias Kouchakji, Joanne C. Imperial, Ewa Carrier	2017	8
14	FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. Journal of Clinical Oncology ·Vincent J. Picozzi, J. Marc Pipas, Albert C. Koong, Amato Giaccia, Nathan Bahary, Smitha Krishnamurthi, Charles D. Lopez, Peter J. O’Dwyer, Katharina Modelska, Vanessa Poolman, James Chou, Ming Zhong, Seth Porter, Tom Neff, Frank H. Valone	2013	6
15	Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results Ganesh Raghu, Mary Beth Scholand, João A. de Andrade, Lisa Lancaster, Jonathan Goldin, Seth Porter, Thomas B. Neff, Frank H. Valone, John L. Stauffer	2012	5
16	Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). Journal of Clinical Oncology ·Vincent J. Picozzi, Flavio G. Rocha, Scott Helton, Kabir Mody, Horacio J. Asbun, Michael J. Pishvaian, Patrick G. Jackson, Tina Etheridge, Mairead Carney, Thomas B. Neff, Seth Porter, Gerald Crans, Frank H. Valone, Wen Shi	2016	2
17	Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial SSRN Electronic Journal ·Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel, Carlo Albera, David J. Lederer, Kevin R. Flaherty, Neil Ettinger, Rafael L. Perez, Mary Beth Scholand, Jonathan Goldin, Kin-Hung P. Yu, Thomas B. Neff, Seth Porter, Ming Zhong, Eduard Gorina, Elias Kouchakji, Ganesh Raghu	2019	1
18	Gemcitabine/Nab-Paclitaxel and Pamrevlumab in Locally Advanced Pancreatic Cancer (LAPC): A Phase 1/2 Trial SSRN Electronic Journal ·Vincent J. Picozzi, Flavio G. Rocha, Jordan Winter, Michael J. Pishvaian, Kabir Mody, John A. Glaspy, Timothy Larson, Marc Matrana, Mairead Carney, Ming Zhong, Seth Porter, Elias Kouchakji, Tom Neff, Ewa Carrier	2019	1
19	Automatic quantitative fibrosis scores at baseline is a predictor of progression in patients with IPF GraceHyun Kim, Matthew Brown, Jonathan Goldin, Peiyun Lu, Eduard Gorina, Seth Porter	2017	1
20	Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF Jonathan Goldin, Grace Kim, Peiyun Lu, Seth Porter, Eduard Gorina, Matthew A. Brown	2017	1

About Seth Porter

Seth Porter is a scholar working on Pulmonary and Respiratory Medicine, Biochemistry, Pathology and Forensic Medicine, Internal Medicine and Oncology, having authored 21 papers that have together received 799 indexed citations. Recurring topics across this work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Connective Tissue Growth Factor Research (7 papers), Pancreatic and Hepatic Oncology Research (6 papers), Systemic Sclerosis and Related Diseases (5 papers), Renal cell carcinoma treatment (4 papers), TGF-β signaling in diseases (2 papers), Blood transfusion and management (2 papers) and Pulmonary Hypertension Research and Treatments (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (287 citations), Biochemistry (45 citations), Immunology (129 citations), Hematology (57 citations) and Oncology (125 citations). Seth Porter has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include Jonathan Goldin, Ganesh Raghu, Kevin R. Flaherty, Thomas B. Neff, Mary Beth Scholand, Stanley C. Froehner, Elias Kouchakji, Ming Zhong, Luca Richeldi and Eduard Gorina. Their work appears in journals such as Journal of Clinical Oncology, Transfusion, Journal of Pharmaceutical Sciences, ESMO Open and The Lancet Respiratory Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact